Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

265 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with memory disorders are experiencing different trends which are difficult to predict. Moreover, the distinction between Lewy body disease and Alzheimer's disease is not easy as both diseases can present similar symptoms. Nowadays, routine examinations exist and can improve the diagnosis but there are not specific enough of one of those two pathologies.

Lewy body disease is characterized by the presence of particular structures in patient's brain, called "Lewy body", composed of a protein called "alpha-synuclein". The aim of this study is to measure the rate of alpha-synuclein in cerebrospinal fluid. This measurement could allow us to differentiate patient with Alzheimer's disease from those with Lewy body disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies

NCT07166744

Dementia With Lewy Bodies (DLB) Alzheimer's Disease (AD)

NOT_YET_RECRUITING NA

Natural History and Disease Progression Biomarkers of Multiple System Atrophy

NCT04229173

Multiple System Atrophy

COMPLETED NA

Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment

NCT06965816

Alzheimer's Disease Hippocampus Brain Atrophy +4 more

COMPLETED

Amyloid Beta-peptide 1-40 and Alzheimer's Disease

NCT02770482

Alzheimer Disease

COMPLETED NA

MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems

NCT00413621

Alzheimer's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

"Alzheimer's Disease" and "Lewy Body Disease"

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"Alzheimer's Disease" arm

Patient with Alzheimer's disease

Group Type OTHER

MRI

Intervention Type OTHER

lumbar puncture

Intervention Type PROCEDURE

neuropsychological tests

Intervention Type BEHAVIORAL

"Lewy Body Disease" arm

Patient with Lewy Body Disease

Group Type OTHER

MRI

Intervention Type OTHER

lumbar puncture

Intervention Type PROCEDURE

neuropsychological tests

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

Intervention Type OTHER

lumbar puncture

Intervention Type PROCEDURE

neuropsychological tests

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 45 years of age
* Subject agrees to participate in the study
* Subject meets the criteria Dubois et al., 2007. for diagnosis of probable AD.
* Subject with a syndromic presentation of mild cognitive impairment or mild dementia
* Subject has a study partner who is able to provide accurate information about the patient
* Subject affiliated to a social security scheme

Exclusion Criteria

* Patient who meets both AD and Lewy Body disease criteria
* Contraindications to lumbar puncture
* Contraindications to an MRI scan
* Subject who is not affiliated to a social security scheme
* Subject under guardianship or curatorship
* Subject under judicial protection
* Subject refuses to participate in the study
* Subject has evidence of clinically relevant neurological disorder (fronto-temporal dementia, brain tumor, stroke, …) that led to persistent cognitive disorders
* Subject has evidence of clinically relevant psychiatric disorders (schizophrenia, major depression, …)
* Pregnant or attempting to become pregnant women
* Subject's vision and audition is sufficient for neuropsychological tests's assessment, based on the investigator's judgment.

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No